In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 31 for your search:
Drug:  yttrium Y 90 ibritumomab tiuxetan
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Sor451107ctil, NCT00463463
2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: SHEBA-07-4466-AN-CTIL, NCT00491491
3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPI-ZEV-11-301, NCT01510184
4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPI-ZEV-12-302, NCT01662102
5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 6th radioimmunotherapy prot., EudraCT number: 2007-002762-35, NCT00761384
6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: ZEV0701, NCT00807196
7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 05H9, STU00004871, NU-0522-060, MILLENNIUM-NU-05H9, NCT00372905
8.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BIDMC-2003P-000182, NCT00073957
9.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: BIDMC-2004P-000044, NCT00110149
10.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BMA-05-017-ZEV, NCT00438581
11.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 05149, P01CA030206, CHNMC-05149, CDR0000579136, NCI-2010-01230, NCT00577278
12.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000588042, USCTU-SCHRIFT-06-DOG05-44, USCTU-SCHRIFT, USCTU-RHM-CAN0542, EUDRACT 2007-000222-51, EU-20819, SCHRIFT-06-DOG05-44/RHM-CAN0542, NCT00637832
13.

Phase: Phase II
Type: Treatment
Status: Active
Age: 65 to 80
Sponsor: Other
Protocol IDs: CDR0000589530, CALACASS-3RCHOPZ, INCA-RECF0624, EUDRACT-2006-006179-19, CALACASS-2006/27, 3 R CHOP Z, NCT00690560
14.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GELTAMO-Z-BEAM LDGGB, EudraCT No.: 2007-003198 - 22, NCT00646750
15.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000597508, P30CA023074, UARIZ-HSC-0567, HSC#0567, UARIZ-SRC17899, 05-0303-01, NCT00732498
16.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 07076, P01CA030206, P30CA033572, CHNMC-07076, CDR0000597569, NCT00695409
17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GOTEL-FL1LC-0701, Eudra-CT 2007-003091-19, NCT00722930
18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZETAL07, NCT00902525
19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EPROST-20060078, SCCC-2005133, WIRB-20060249, SCCC-20060249, SCCC-20060078, NCT00453102
20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: IRB #14228, NCT01130194
21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Zevalin, NCT01207765
22.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1001, S1001, NCT01359592
23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2398.00, NCI-2011-01189, NCT01434472
24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ZEVISS, NCT01446562
25.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2011-0393, NCT01490723
1   
New Search